Medicare’s GLP-1 Bridge Is Live: What Providers and Billing Teams Need to Know

The Medicare GLP-1 Bridge is now live—and it does not work like ordinary Part D coverage. For physicians who prescribe weight-management medications to Medicare patients, the program creates a workflow that may look familiar at first but differs in several important ways: the Bridge operates outside the Part D payment and coverage flow, uses its own prior authorization process, and routes pharmacy claims through a CMS-designated central processor.

Eligible beneficiaries can obtain certain GLP-1 medications for $50 per month when prescribed for weight management. But the key question for practices is not simply whether a patient qualifies for a GLP-1. It is whether the patient qualifies for this specific coverage pathway, whether the prescription is being written for the indication the Bridge covers, and whether the documentation submitted to CMS supports that determination. That distinction matters because a prescription can be clinically appropriate and still be ineligible for the Bridge.

For practices, the bigger issue is workflow. The Bridge creates a new point at which eligibility, documentation, prior authorization, prescription details, and pharmacy processing all have to line up. A practice that treats the Bridge like a standard Part D prior authorization may create avoidable delays, rejected requests, or additional work for staff.

What the Medicare GLP-1 Bridge Actually Is

The Medicare GLP-1 Bridge is a CMS Section 402 demonstration running from July 1, 2026, through December 31, 2027. CMS created it to provide eligible Medicare Part D beneficiaries access to certain GLP-1 drugs for reducing excess body weight and maintaining weight reduction.

It is not a new Medicare Part D benefit. That is the first distinction practices need to understand.

Under the Bridge, participating manufacturers provide eligible drugs at a negotiated net price, while the beneficiary pays a fixed $50 copay. The copay does not count toward the beneficiary’s Part D true out-of-pocket costs, the Part D deductible does not apply, and low-income subsidy assistance does not reduce the $50 amount.

The program is nationwide, but eligibility is limited. A Medicare beneficiary must be enrolled in an eligible Part D plan type, use the medication for a covered weight-management purpose, and meet the Bridge’s clinical criteria.

Importantly, a Part D denial is not required before a claim can be submitted to the Bridge. If the prescriber believes the patient may qualify, the pharmacy can submit the claim directly to the Bridge.

For practices, that makes the Bridge less like a traditional insurance benefit and more like a separate coverage-and-authorization pathway attached to the prescription. That difference should be reflected in the practice’s internal workflow rather than left to individual staff members to interpret case by case.

Who Is Actually Eligible?

The Bridge is not available to every Medicare beneficiary who wants a GLP-1 for weight loss. Eligibility depends first on the beneficiary’s Part D plan type. Standalone Medicare Prescription Drug Plans (PDPs) and eligible Medicare Advantage prescription drug plans (MA-PDs) can participate. Certain Special Needs Plans, employer/union group waiver plans, and LI NET beneficiaries may also qualify, while other Medicare plan arrangements are excluded unless the beneficiary has qualifying standalone Part D coverage.

There is then a clinical eligibility test. The prescriber must attest that the medication is being used to reduce excess body weight and maintain weight reduction, together with ongoing lifestyle modification that includes structured nutrition and physical activity consistent with the applicable FDA-approved labeling.

The clinical thresholds are based on the patient’s BMI when GLP-1 therapy was initiated, not necessarily the patient’s BMI on the day the prior authorization request is submitted.

The principal pathways are:

• BMI ≥35 at initiation; or
• BMI ≥30 at initiation plus heart failure with preserved ejection fraction, uncontrolled hypertension as defined by CMS, or chronic kidney disease stage 3a or higher; or
• BMI ≥27 at initiation plus prediabetes, previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease.

The beneficiary must be at least 18 years old. That historical-BMI requirement is one of the most operationally important details in the entire program.

A patient may have started therapy years ago at a qualifying BMI and now have a substantially lower BMI. That does not automatically disqualify the patient. CMS specifically instructs prescribers to attest to the qualifying BMI at the time therapy was initiated.

For practices, this means that old clinical documentation can suddenly become relevant to a current coverage request. That creates a practical documentation challenge. If the historical BMI is not clearly documented, staff may have difficulty substantiating the information the provider is required to attest to.

The Diagnosis Matters—but So Does the Indication

One of the easiest ways to misunderstand the Bridge is to treat it as a general mechanism for obtaining a GLP-1 whenever a Part D plan does not cover the drug. It is not. The Bridge is designed for beneficiaries using an eligible GLP-1 for weight management. Certain other indications are already coverable under the Medicare Part D benefit and therefore are outside the Bridge.

CMS specifically identifies type 2 diabetes, moderate-to-severe obstructive sleep apnea, and noncirrhotic MASH with moderate-to-advanced liver fibrosis as Part D-covered indications. If the GLP-1 is prescribed for one of those indications, the patient should obtain coverage through the Part D plan rather than through the Bridge.

The same distinction matters for cardiovascular risk reduction. A patient may meet a Bridge BMI criterion and also have established cardiovascular disease. That does not automatically make the patient ineligible for the Bridge. The key question is the treatment indication: if the drug is being prescribed to reduce the risk of major adverse cardiovascular events, the prescription should be routed through the patient’s Part D plan.

For the physician, the practical rule is simple: Document the actual treatment indication clearly. Do not treat the Bridge as a fallback payer when ordinary Part D coverage is unavailable. For the practice, there is a second rule: Make sure the indication in the PA request, the medical record, and the prescription workflow tells the same story.

A mismatch between the clinical record and the information submitted for the Bridge can create an avoidable administrative problem even when the patient may otherwise qualify.

Which Drugs Are Included?

As of the current CMS guidance, the Bridge covers the following products when used for weight management:

• Foundayo
• Wegovy, including injection and tablet formulations
• Zepbound KwikPen

CMS specifically excludes the single-dose vial and single-dose pen formulations of Zepbound from the Bridge. CMS also notes that the covered-product and NDC list may be updated during the demonstration.

That last point matters to billing and pharmacy teams. A product being in the same therapeutic category does not mean that every formulation or NDC is automatically payable under the Bridge. The claim is adjudicated against the program’s current product and NDC requirements.

For practices, that means staff should avoid relying on a generic “GLP-1” category when confirming the prescription. The exact product and formulation matter.

The Prescribing Workflow Is Different

This is where practices should pay particularly close attention. The prescriber does not simply submit a traditional Part D prior authorization to the patient’s insurance plan. CMS requires the provider to submit a prescription for an eligible drug and a Medicare GLP-1 Bridge prior authorization request. CMS encourages electronic submission, with fax available as an alternative.

There is also an unusual sequencing requirement:

• The prescription should go to the pharmacy first. The prescriber should wait for the pharmacy to submit the claim and request the prior authorization before submitting the PA request.
• CMS warns that submitting the PA before the pharmacy claim establishes the beneficiary in the Bridge system can result in a “patient not found” error.

That is exactly the kind of detail that can turn a clinically straightforward prescription into an avoidable administrative problem. A practice should therefore avoid building its workflow around the assumption that the physician submits the PA first and the pharmacy processes the prescription afterward. Under the Bridge, the sequence matters. It also means that responsibility should be clearly assigned. Someone in the practice needs to know who monitors the pharmacy request, who completes the PA, who follows up on missing information, and who confirms the outcome.

What Happens If the PA Request Does Not Arrive?

CMS provides a defined escalation path. Pharmacies generally transmit the PA request to the prescriber within 24–72 hours. If the request has not arrived after 72 hours, the prescriber may submit the Bridge fax form directly.

CMS says PA decisions are communicated within 72 hours of submission.

For practices, those timeframes create a useful internal escalation rule: do not allow a missing PA request to sit unresolved simply because the prescription has already been sent to the pharmacy.

A simple tracking process can help staff distinguish between:

• prescription sent but no pharmacy claim;
• pharmacy claim submitted but PA request not received;
• PA submitted and pending;
• eligibility rejection;
• clinical-criteria issue; and
• product or formulation issue.

Those categories point to different problems and should not all be handled as generic “insurance delays.”

What Does the Billing Team Actually Need to Know?

For most physician practices, the Bridge does not create a new professional claim for the medication itself. The drug claim is processed through the pharmacy benefit infrastructure, with the central processor adjudicating the pharmacy claim. That does not make the billing or revenue-cycle team irrelevant. It changes where the administrative work sits.

For physician practices, the operational burden is primarily on documentation, prior authorization, eligibility, indication, and coordination with the dispensing pharmacy—not on submitting a traditional professional claim for the drug.

The pharmacy submits the drug claim; the physician’s office supplies the clinical information that determines whether the claim can proceed.

CMS says the Bridge is the primary payer for covered Bridge claims and does not coordinate benefits with other payers. The central processor uses the NCPDP Telecommunication Standard for electronic pharmacy claims; paper claims and direct member reimbursement are not accepted.

For practices, that means the most useful internal question is not: “What CPT code do we bill?” It is: “Who owns the Bridge workflow from prescription through PA approval and pharmacy dispensing?” If the answer is unclear, the practice is already exposed to avoidable delays.

This is also where a well-defined revenue-cycle process can help. Even when the medication itself is processed through the pharmacy channel, the practice still needs a reliable process for tracking the clinical documentation, PA status, payer or benefit information, and unresolved requests.

The $50 Copay Comes With an Important Catch

The $50 price is straightforward for the beneficiary but operationally unusual for Medicare. The Bridge copay is not treated like ordinary Part D cost-sharing. It does not count toward TrOOP, the Part D deductible does not apply, and LIS does not reduce it. Coupons and discount programs also cannot be used to reduce the Bridge copay. The $50 copay remains the same regardless of where the beneficiary is in the Part D benefit. That distinction matters when staff explain the program to patients.

A patient who is accustomed to Medicare’s Part D cost-sharing rules may reasonably assume that the $50 payment will accumulate toward the annual Part D out-of-pocket limit. Under the Bridge, it does not. This is a patient-communication issue as much as a billing issue.

Prior Authorization Is Not the Same as a Part D Appeal

Another important difference is what happens when CMS does not approve the request. There is no appeals process under the Medicare GLP-1 Bridge. If the prescriber entered incorrect information or has new or additional information, the PA request can be resubmitted. But the Bridge itself does not provide the standard Part D appeals pathway.

That makes the accuracy of the initial submission especially important. Before submitting a request, practices should make sure the record supports:

• the actual treatment indication;
• the qualifying BMI at therapy initiation;
• the relevant diagnosis supporting the applicable BMI threshold;
• the ongoing lifestyle-modification requirement;
• the specific drug and formulation being prescribed; and
• the patient’s current Medicare Part D eligibility and plan type.

This is not about documenting more than CMS requires. It is about making sure the information being attested to is accurate, internally consistent, and supportable.

For practices, that creates an important operational lesson: the best time to find a documentation gap is before the PA is submitted, not after the request has already been rejected.

The Prescriber’s Attestation Is a Compliance Issue

The prior authorization form is not merely an administrative checkbox. CMS states that the prescriber completing the request is attesting, under penalty of perjury, that the information submitted is accurate and complete. CMS may independently verify information against Medicare data, including whether a beneficiary has a relevant diagnosis. That raises the compliance stakes for practices. The person completing the PA should not be relying on a patient’s recollection of a historical BMI, an outdated problem-list entry, or an assumption about why the medication is being prescribed. The supporting medical record should be capable of substantiating the attestation.

For organizations with centralized prior authorization teams, this is a good reason to define who may complete and submit Bridge requests and what documentation must be reviewed before the provider’s attestation is made.

It is also a good reason to periodically audit the workflow. A practice can have a clinically appropriate patient and still create avoidable risk if staff routinely copy forward information, use outdated documentation, or submit PA requests without confirming that the record supports the attestation.

One More Eligibility Trap: Prior Part D Use

CMS has also created an important exclusion based on prior Part D use of GLP-1 medications. For 2026, CMS will review its data to determine whether the beneficiary previously received a GLP-1 through their Part D plan. The review includes a broader group of GLP-1 products, including drugs such as Ozempic, Mounjaro, Rybelsus, Trulicity, Victoza, Wegovy, and Zepbound.

A beneficiary who has received a covered GLP-1 through Part D during the relevant 2026 period may be ineligible for the Bridge. CMS has not yet determined the applicable lookback period for 2027. This creates a practical situation that practices should anticipate: a patient may appear clinically eligible based on the Bridge criteria but still receive a pharmacy rejection because CMS data shows prior Part D use.

That type of rejection reflects Bridge eligibility rules rather than necessarily indicating that the prescribed medication is clinically inappropriate.

For staff, that distinction matters. A clinical-criteria problem may require additional documentation. A prior-Part-D-use rejection may require a completely different response. Not every rejection is a documentation problem, and not every rejection should be handled by resubmitting the same PA.

What Happens After the First Approval?

Bridge approval is not intended to create a new PA requirement every time the patient needs a refill. Once a Medicare GLP-1 Bridge prior authorization is approved, the approval remains valid through December 31, 2027. Subsequent fills generally do not require a new prior authorization unless the beneficiary switches to a different covered GLP-1 product.

That makes it important for practices to distinguish between a new therapy or product change and an ordinary refill. The Bridge also limits dispensing to a single 28- or 30-day supply per fill. Sixty- and 90-day fills are not available under the program.

Bridge Workflow at a Glance

1. Identify the coverage pathway
Weight management → potentially Bridge; Part D-covered indication → Part D.

2. Verify eligibility
Confirm plan type, age, qualifying historical BMI, and applicable clinical criteria.

3. Send the prescription
The prescription goes to the pharmacy first.

4. Pharmacy submits the claim
The pharmacy processes the claim through the Bridge and requests PA when required.

5. Complete the PA
The provider submits the requested clinical information and required attestation.

6. Resolve the request
Monitor the PA decision and distinguish administrative or eligibility rejections from clinical-criteria issues.

7. Coordinate dispensing
If approved, the beneficiary receives the covered monthly supply for the $50 copay.

What Practices Should Do Now

The Medicare GLP-1 Bridge is sufficiently different from ordinary Part D processing that practices should not leave the workflow to individual staff members to figure out case by case. A workable approach is to establish a short internal checklist.

First, identify the coverage pathway before submitting the PA. Determine whether the prescription is for weight management under the Bridge or for an indication that belongs under the patient’s Part D benefit.

Second, capture the qualifying historical BMI. If the patient started GLP-1 therapy before the Bridge launched, the relevant BMI is the BMI at initiation. Make sure the medical record supports the number being attested to.

Third, verify the indication. A diagnosis in the chart is not necessarily the indication for which the drug is currently being prescribed. The PA should accurately reflect the treatment purpose.

Fourth, verify the exact product and formulation. Especially for Zepbound, formulation matters.

Fifth, follow the Bridge sequencing rules. Send the prescription to the pharmacy first and wait for the pharmacy claim/PA request before submitting the Bridge PA.

Sixth, assign ownership. Decide whether the physician, clinical staff, centralized PA team, or another designated employee is responsible for completing the Bridge request and following it through to resolution.

Finally, monitor rejections rather than treating every rejection as a coverage denial. “Patient not found,” prior Part D use, an ineligible plan type, a non-covered formulation, and a clinical-criteria problem point to different underlying issues and require different responses.

A Practical Workflow Review Can Prevent Avoidable Delays

For practices that are already handling a high volume of prior authorizations, the Bridge is another example of why payer and program-specific workflows need to be monitored rather than treated as one-time setup tasks.

A practice should know:

• where Bridge documentation is stored;
• who verifies historical eligibility information;
• who reviews the exact drug and formulation;
• who monitors the pharmacy-to-provider PA request;
• who tracks pending requests;
• who reviews rejection reasons; and
• when a case should be escalated for additional billing, coding, or documentation review.

That process does not have to be complicated. But it does need to be defined.

Where WCH Can Help The Medicare GLP-1 Bridge is primarily a pharmacy benefit workflow, but the information required to make that workflow succeed often starts inside the physician’s office. That creates several areas where practices can strengthen their processes: Documentation review: Is the medical record sufficient to support the information being submitted? Coding and diagnosis review: Does the documented diagnosis accurately support the treatment and the information submitted? PA workflow: Are requests being completed in the correct sequence and within the appropriate timeframe? Claims and rejection analysis: Are staff distinguishing eligibility, formulation, documentation, and other rejection types instead of treating every problem as a generic denial? Process auditing: Are Bridge requests being handled consistently across providers and staff? Revenue-cycle support: Are recurring administrative problems being identified and corrected rather than handled repeatedly on a case-by-case basis? WCH can support practices through medical billing, coding audits, documentation and claims review, and revenue-cycle support—helping identify workflow gaps that can delay reimbursement or patient access. The goal is not to turn the billing team into a pharmacy benefits department. It is to make sure the practice’s side of the Bridge workflow is accurate, documented, and consistently managed.

The Bigger Picture for Physicians

The Medicare GLP-1 Bridge is a small program compared with the Medicare Part D benefit, but it illustrates a larger change in how prescription coverage is being administered.

The physician is no longer simply writing a prescription and sending a standard prior authorization to an insurer. In this model, the prescribing indication, historical clinical data, product configuration, beneficiary eligibility, PA sequence, and pharmacy claim all have to line up. That makes the administrative workflow part of the coverage decision.

For physicians, the lesson is not to become experts in pharmacy claims processing. It is to recognize which details of the clinical record now have direct consequences for access to treatment. For billing and administrative teams, the lesson is equally straightforward:

The Medicare GLP-1 Bridge is not just a $50 drug benefit. It is a separate coverage pathway with its own eligibility rules, documentation requirements, claim routing, and failure points. Practices that build that workflow now will spend far less time later explaining why a prescription that looked covered on paper never made it through the pharmacy counter. And for practices already dealing with complex payer requirements, the broader lesson is even more important:

Coverage changes do not create value simply because staff know the new rule. They create value when the rule is translated into a reliable workflow that prevents avoidable rejections, delays, and rework.

That is where strong billing, documentation, coding, and revenue-cycle processes become more than administrative support—they become part of how a practice protects both patient access and its own operational efficiency.

Sources

• Centers for Medicare & Medicaid Services, “Medicare GLP-1 Bridge — Overview and FAQs,” updated July 13, 2026.
• Centers for Medicare & Medicaid Services, “Information for Providers — Medicare GLP-1 Bridge,” updated August 6, 2026.
• Centers for Medicare & Medicaid Services, “Information for Pharmacies — Medicare GLP-1 Bridge.”
• Centers for Medicare & Medicaid Services, “Information for Part D Plans — Medicare GLP-1 Bridge.”
• Centers for Medicare & Medicaid Services, “CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications,” July 1, 2026.
• Centers for Medicare & Medicaid Services, “CMS Releases Educational Materials for the Medicare GLP-1 Bridge,” June 3, 2026.